PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Flavoxate hydrochloride - Overactive bladder (adults)

PAD Profile : Flavoxate hydrochloride - Overactive bladder (adults)

Keywords :
antimuscarinics, OAB, urge incontinence, urinary incontinence, urinary frequency, LUTS, urinary urgency, anticholinergics
Brand Names Include :
Urispas

Traffic Light Status

Status 1 of 1.

Status :
Non Formulary
Formulations :
  • Not Specified
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
NFD1
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
06 March 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The APC supports patients in trialling a treatment break of their overactive bladder medicines.

A "Leaflet for trial of stopping anticholinergics" can be found in the documents section.

05 July 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

Flavoxate is non-formulary.

Solifenacin is the 1st line treatment option.

Tolterodine immediate release tablets or Trospium are 2nd line options in patients for whom solifenacin is not suitable.

05 February 2020
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

Flavoxate is not recommended for treating overactive bladder in line with NICE NG123 - guidance can be found below

Associated BNF Codes

07. Obstetrics, Gynaecology and Urinary-Tract Disorders
07.04.02. Drugs for urinary frequency enuresis and incontinence
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More